

# New Hampshire Medicaid Fee-for-Service Program Spinraza® (nusinersen) Criteria

Approval Date: January 14, 2022

## **Criteria for Approval**

- Patient must have documentation of a confirmed diagnosis of spinal muscular atrophy (SMA);
  AND
- 2. Genetic testing is required to demonstrate SMN1 homozygous gene deletion or mutation; AND
- 3. Quantitative spot urine protein testing at baseline and prior to each dose; AND
- 4. Complete blood count at baseline and prior to each dose; **AND**
- 5. Nusinersen must be administered by a specialist with competency in intrathecal injection; **AND**
- 6. Patient has not received a previous treatment with Zolgensma®; AND
- 7. Patient is not currently receiving therapy with Evrysdi® (risdiplam); AND.
- 8. Provide baseline assessment using at least one of the following:
  - a. Hammersmith Functional Motor Scale Expanded (HFMSE)
  - b. Hammersmith Infant Neurologic Exam (HINE)
  - c. Six-minute walk test (6MWT)
  - d. Upper limb module (ULM) score

#### **Criteria for Renewal**

- 1. Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include serious infections, life-threatening glomerulonephritis, thrombocytopenia, etc.; **AND**
- 2. Patient has demonstrated improvement or lack of progression in at least one of the following:
  - a. Hammersmith Functional Motor Scale Expanded (HFMSE)
  - b. Hammersmith Infant Neurologic Exam (HINE)
  - c. Six-minute walk test (6MWT)
  - d. Upper limb module (ULM) score

Proprietary & Confidential

© 2003–2022 Magellan Health, Inc. All rights reserved.

Magellan Medicaid Administration, part of the Magellan Rx Management division of Magellan Health, Inc.

#### **Quantity Limit:**

• Initial: Four vials for the first 58 days

• Maintenance: One vial every 120 days

### Length of Approval:

• Initial: Six months

• Renewal: One year

## **Criteria for Denial**

Criteria for approval not met.

#### References

Available upon request.

## **Revision History**

Reviewed by	Reason for Review	Date Approved
DUR Board	New	10/24/2017
Commissioner	Approval	12/05/2017
DUR Board	Revision	03/12/2019
Commissioner Designee	Approval	04/05/2019
DUR Board	Revision	06/30/2020
Commissioner	Approval	08/07/2020
DUR Board	Revision	12/02/2021
Commissioner Designee	Approval	01/14/2022

